Cologuard® revenue increased 78 percent to $103 million during second quarter

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. S
10. COF

Go back to Cologuard® revenue increased 78 percent to $103 million during second quarter

Exact Sciences (EXAS) PT Lowered to $65 at Cowen; Buy on Weakness

August 2, 2018 7:56 AM EDT

Cowen lowered its price target on Exact Sciences (NASDAQ: EXAS) to $65.00 (from $85.00) while maintaining a Outperform rating following Q2 miss.

Analyst Doug Schenkel commented, "EXAS missed Q2 revenue and volume expectations. While we think this could have been better explained, further... More

Exact Sciences (EXAS) Tops Q2 EPS by 3c, Revs Miss; Maintains Outlook

August 1, 2018 4:09 PM EDT

Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.30), $0.03 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $102.9 million versus the consensus estimate of $104.66 million.

GUIDANCE:

Exact Sciences sees FY2018 revenue of $420-430 million, versus the consensus... More